HSBC TUR.WAR.OP.END. 6MK/ DE000HS36L06 /
10/4/2024 9:37:11 PM | Chg.-0.0300 | Bid9:59:57 PM | Ask9:59:57 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.2400EUR | -11.11% | 0.2300 Bid Size: 50,000 |
0.2900 Ask Size: 50,000 |
Merck and Co Inc | 107.617 USD | 12/31/2078 | Call |
GlobeNewswire
7/31
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
GlobeNewswire
7/17
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease a...
GlobeNewswire
6/11
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next...
GlobeNewswire
6/6
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepin...
GlobeNewswire
5/28
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
GlobeNewswire
5/23
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
GlobeNewswire
5/16
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
5/14
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
GlobeNewswire
5/8
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
4/24
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Onc...
GlobeNewswire
4/15
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness